Login
Navigate Fool.com
Will CELG beat
the market?

Celgene

NASDAQ: CELG

Community Rating: 4 Stars: Favorite

144.82 -1.82 (-1.24%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $148.09
Previous Close $146.64
Daily Range $144.08 - $148.09
52-Week Range $110.53 - $174.66
Market Cap $58.8B
P/E Ratio 43.51
Dividend (Yield) $0.00 (0.0%)
Volume 3,407,559
Average Daily Volume 4,359,623
Current FY EPS $6.34

How do you think CELG
will perform against the market?

Top CELG Bull/Bear Pitches

 

Jeffreyw (< 20)
Submitted October 25, 2010

Big investment in discovery and production of new therapies. Monitizing these treatments will take time, but could be huge.

0 Replies Reply Report this Post
 

NetscribeBiotech (< 20)
Submitted February 22, 2007

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for EN … More

1 Replies Reply Report this Post

News & Commentary

3 Reasons Celgene Will Bounce Back This Year

Celgene's stock has suffered with biotech's fall this year, but this top health-care stock's poised for long-term success.

Here's What This Billion-Dollar Financial Advisor Has Been Buying and Selling

Douglass Winthrop has made big moves involving Linn Energy, Intel, Celgene, and Seadrill.

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

5 reasons to care about Ackman's Botox bet

What to Watch for in Biotech Earnings This Week

Several top biotechs will report earnings this week. Will they reignite the biotech rally or drive share prices even lower?

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Here's what you need to know about Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) before they report their first quarter earnings later this month.

The S&P 500's 3 Biggest Biotech Losers of 2014

It's been a rough year for biotech, especially for these three S&P 500 stocks.

3 Biotech Opportunities Following This Selloff

Here's a second chance to invest in companies with viable growth potential.

See More CELG News...

Sector

Healthcare

Industry

Drugs

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks